Silence
Silence Therapeutics Inks Deal to Access Genomics England Database
Silence Therapeutics aims to use the database to help identify new drug targets, as well as for patient recruitment and stratification in clinical trials.
According to its CEO, Silence is aiming to expand into a "full-functioning biotech" with more than just a single product.
NEW YORK (GenomeWeb) – Silence Therapeutics this month disclosed that it was ending its work with investigational sepsis drug Atu112 amid disappointing results in preclinical testing.
NEW YORK (GenomeWeb) – Silence Therapeutics this week announced the publication of preclinical data showing that its acute lung injury drug Atu111 could reduce the severity of sepsis-related illness and improve survival in mice.
NEW YORK (GenomeWeb) – Silence Therapeutics this week announced that it has completed patient recruitment for a Phase IIa trial of its siRNA-based cancer drug Atu027.
Jul 17, 2014
Nov 21, 2013
Jun 20, 2013
May 30, 2013
Apr 11, 2013
Mar 21, 2013
Mar 7, 2013
Jan 3, 2013
People: Michael Khan
Premium
Oct 11, 2012
Sep 20, 2012
People in the News: Michael Khan
Premium
Sep 13, 2012
Aug 23, 2012
Jul 12, 2012
Jun 7, 2012
Mar 22, 2012
Mar 15, 2012